NCT05891119 - Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 3, 2023

Primary Completion Date

August 21, 2024

Study Completion Date

December 26, 2024

Conditions

Atopic Dermatitis

Interventions

DIETARY_SUPPLEMENT

Caffeine

Oral liquid

DRUG

Metoprolol

Oral tablet

DRUG

Midazolam

Oral liquid

DRUG

Warfarin

Oral tablet

DIETARY_SUPPLEMENT

Vitamin K

Oral tablet

DRUG

Omeprazole

Oral capsule

DRUG

Rocatinlimab

Subcutaneous injection

Trial Locations (7)

DermDox Dermatology Centers, PC - Camp Hill, Camp Hill

Axis Clinicals, LCC, Dilworth

Velocity Clinical Research, North Hollywood, North Hollywood

Accel Research Sites (ACR), DeLand

Direct Helpers Research Center (DHRC), Hialeah

Velocity Clinical Research -Spartanburg, Spartanburg

DermDox Dermatology Centers, PC - Sugarloaf, Nashville